Education Program
Biological therapies, Bispecific Antibody Therapy, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Therapies, Lymphoid Malignancies, Technology and Procedures
Seaport Ballroom ABCD
(Manchester Grand Hyatt San Diego)
Description:
How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma? CAR T-Cells and Bispecific Antibodies The introduction of immune based therapeutics such as bispecific antibodies and chimeric antigen receptor engineered T cells (CAR T) has revolutionized the treatment of relapsed and/or refractory multiple myeloma. Such therapies targeting plasma cell antigens such as the B-cell maturation antigen (BCMA), G-protein coupled receptor family C group 5 member D (GPRC5D) and Fc Receptor Like 5 (FCRL5) lead to deep and durable responses in triple class and penta-refractory myeloma patients. These therapies also introduced a new set of challenges related to their unique toxicities and their management as well as the understanding of the optimal way to administer and sequence them. Dr. Nizar J.Bahlis will discuss the current use of bispecific antibodies to treat multiple myeloma. In addition the mechanisms that mediate the acquired resistance or escape to bispecific antibodies will be outlined while providing a guidance to the optimal administration and sequencing of these drugs. Dr. Sham Mailankody will review the currently approved CAR T cells in multiple myeloma as well as other CAR T cell platforms currently under clinical investigations. He will also discuss the optimal usage and sequencing of CAR T cells in the context of other multiple myeloma therapies. Dr. Surbhi Sidana, will review the toxicities associated with bispecific antibodies and CAR T cells, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), delayed neurotoxicity, cytopenias, and infection. She will also provide guidance on how to manage these toxicities.
Chair:
Nizar J Bahlis, MD, ARRAY(0xff3b5d4)
Disclosures:
Bahlis: Forus: Consultancy, Honoraria; GSK: Consultancy, Other: member of steering committee; BMS: Consultancy, Honoraria; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Honoraria, Other: member of steering committee; Karyopharm therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy; Genentech/Roche: Honoraria; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: IRC member and chair, Research Funding.
How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma? CAR T-Cells and Bispecific Antibodies The introduction of immune based therapeutics such as bispecific antibodies and chimeric antigen receptor engineered T cells (CAR T) has revolutionized the treatment of relapsed and/or refractory multiple myeloma. Such therapies targeting plasma cell antigens such as the B-cell maturation antigen (BCMA), G-protein coupled receptor family C group 5 member D (GPRC5D) and Fc Receptor Like 5 (FCRL5) lead to deep and durable responses in triple class and penta-refractory myeloma patients. These therapies also introduced a new set of challenges related to their unique toxicities and their management as well as the understanding of the optimal way to administer and sequence them. Dr. Nizar J.Bahlis will discuss the current use of bispecific antibodies to treat multiple myeloma. In addition the mechanisms that mediate the acquired resistance or escape to bispecific antibodies will be outlined while providing a guidance to the optimal administration and sequencing of these drugs. Dr. Sham Mailankody will review the currently approved CAR T cells in multiple myeloma as well as other CAR T cell platforms currently under clinical investigations. He will also discuss the optimal usage and sequencing of CAR T cells in the context of other multiple myeloma therapies. Dr. Surbhi Sidana, will review the toxicities associated with bispecific antibodies and CAR T cells, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), delayed neurotoxicity, cytopenias, and infection. She will also provide guidance on how to manage these toxicities.
Nizar J Bahlis, MD
Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada
Sham Mailankody, MBBS
Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
Surbhi Sidana, MD
Stanford University School of Medicine, Stanford, CA
denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.